N
SRPT icon

Natixis’s Sarepta Therapeutics SRPT Stock Holding History

Natixis’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437K Buy
24,321
+1,465
+6% +$27.7K ﹤0.01% 861
2026
Q1 		$497K Buy
+22,856
New +$442K ﹤0.01% 815
2025
Q1 		– Sell
-13,456
Closed -$1.64M – 1182
2024
Q4 		$1.64M Buy
13,456
+3,337
+33% +$409K 0.01% 512
2024
Q3 		$1.26M Buy
10,119
+9,653
+2,071% +$1.33M 0.01% 497
2024
Q2 		$73.6K Sell
466
-129
-22% -$16.6K ﹤0.01% 761
2024
Q1 		$77K Buy
+595
New +$72.9K ﹤0.01% 798
2023
Q2 		– Sell
-1,750
Closed -$241K – 1141
2023
Q1 		$241K Sell
1,750
-105,550
-98% -$13.7M ﹤0.01% 726
2022
Q4 		$13.9M Sell
107,300
-30,250
-22% -$3.51M 0.08% 220
2022
Q3 		$15.2M Sell
137,550
-41,100
-23% -$4.14M 0.07% 212
2022
Q2 		$13.4M Buy
178,650
+43,750
+32% +$3.22M 0.05% 246
2022
Q1 		$10.5M Sell
134,900
-102,500
-43% -$7.85M 0.04% 409
2021
Q4 		$21.4M Buy
+237,400
New +$20.3M 0.07% 221
2021
Q2 		– Sell
-5,484
Closed -$409K – 1002
2021
Q1 		$409K Sell
5,484
-160,931
-97% -$14.9M ﹤0.01% 971
2020
Q4 		$28.4M Buy
+166,415
New +$24.7M 0.1% 199
2019
Q1 		– Sell
-39,805
Closed -$4.34M – 875
2018
Q4 		$4.34M Buy
39,805
+26,254
+194% +$3.28M 0.04% 346
2018
Q3 		$2.19M Buy
13,551
+9,197
+211% +$1.26M 0.01% 474
2018
Q2 		$576K Sell
4,354
-3,258
-43% -$307K ﹤0.01% 676
2018
Q1 		$564K Sell
7,612
-5,948
-44% -$397K ﹤0.01% 656
2017
Q4 		$754K Buy
+13,560
New +$718K 0.01% 540

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Natixis's SRPT Position: Q2 2026 in Review

Natixis increased its Sarepta Therapeutics (SRPT) stake by 6.4% in Q2 2026, buying an estimated $27.7K and bringing the position to 24,321 shares worth $437K. The position accounts for ﹤0.01% of the portfolio, ranked #861.

Natixis first reported a position in SRPT in Q4 2017 and has held it in 19 quarters since. The position peaked at $28.4M in Q4 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Natixis held 24,321 shares of Sarepta Therapeutics worth $437K as of Q2 2026.
  • Natixis bought 1,465 Sarepta Therapeutics shares in Q2 2026, an estimated $27.7K.
  • Sarepta Therapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #861 holding.
  • Natixis first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 19 quarters since.
  • Natixis's Sarepta Therapeutics position peaked at $28.4M in Q4 2020.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.